Fig 1: The effect of 5-ASA and PAMAM-5-ASA on the protein expression of IL-6 in Caco-2 cells stimulated with (A) TNF-α or (B) LPS, determined by ELISA in cellular supernatants. Panel C presents the cytokine concentration in control samples. Data are presented as the concentration of cytokine (pg/mL), mean ± SD, n = 4. **p < 0.01, ***p < 0.001, ****p < 0.0001, statistically significant difference compared with untreated control. ^p < 0.05, ^^^p < 0.001, ^^^^p < 0.0001, statistically significant difference compared with TNF-α-treated cells. ††††p < 0.0001, statistically significant difference compared with LPS-treated cells.
Fig 2: The effect of 5-ASA and PAMAM-5-ASA on (A) NFKBIA and (B) IL6 gene expression at the mRNA level in Caco-2 cells, in the presence or absence of ritonavir. The relative level of gene expression was evaluated using quantitative real-time RT-PCR. Data are presented as the percentage of cognate mRNA expression in control (untreated) cells (number of cognate mRNA copies per 1000 copies of geometric-averaged mRNA for reference genes), mean ± SD, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, statistically significant difference compared with the corresponding sample pretreated with ritonavir.
Supplier Page from Biorbyt for Human IL-6/Interleukin-6 ELISA Kit
Application Dilutions: Dilution ratio of 1:1, concentration in serum is target in serum is below detection limit.